Thomas Mathers
Chief Executive Officer at Déclion Pharmaceuticals, Inc.
Profile
Thomas P.
Mathers founded Déclion Pharmaceuticals, Inc. in 2011, where he is working as Chairman & Chief Executive Officer from 2011 and Allievex Corp.
in 2018, where he is working as President, Chief Executive Officer & Director from 2018.
Mr. Mathers also currently works at Biotechnology Innovation Organization, as Director, Aer Therapeutics, Inc., as Independent Director, Pappas Capital LLC, as Partner from 2018, Butler University, as Trustee, and AM Pappas Life Science Ventures V, as General Partner from 2018.
Mr. Mathers also formerly worked at CoLucid Pharmaceuticals, Inc., as Chief Executive Officer in 2017, Peptimmune, Inc., as President & Chief Executive Officer from 2003 to 2011, Cell Based Delivery, Inc., as President & Chief Executive Officer from 2002 to 2003, Cary Street Partners LLC, as Director, Biotechnology Innovation Organization, as Director, CureFAktor Pharmaceuticals LLC, as Director & General Manager from 2012 to 2014, Lifesci Acquisition II Corp., as Independent Director, Pfizer Inc., as Principal, Genzyme Corp., as Vice President-Strategic Development from 1993 to 2001, Snowden Pencer, Inc., as Principal, Cardion GmbH, as Vice President & General Manager from 2001 to 2002, and The United States Army (District of Columbia), as Captain in 1991.
Mr. Mathers received his undergraduate degree in 1988 from US Military Academy.
Thomas Mathers active positions
Companies | Position | Start |
---|---|---|
Déclion Pharmaceuticals, Inc. | Chief Executive Officer | 2010-12-31 |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Private Equity Investor | 2018-04-09 |
Allievex Corp.
Allievex Corp. Pharmaceuticals: OtherHealth Technology Allievex Corp. operates as a biotechnology company. It develops therapies for the treatment of rare pediatric neurodegenerative diseases. The company was founded by Thomas P. Mathers and Eric H. Zanelli and is headquartered in Marblehead, MA. | Founder | 2018-03-31 |
AM Pappas Life Science Ventures V | Corporate Officer/Principal | 2018-01-31 |
Butler University | Director/Board Member | - |
Aer Therapeutics, Inc.
Aer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aer Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Raleigh, NC. The company's mission is to advance the treatment paradigm for mucus mediated lung diseases. The company is dedicated to delivering a therapeutic solution to patients suffering from muco-obstructive lung diseases, with their initial focus being on chronic obstructive pulmonary disease (COPD) and other muco-obstructive lung diseases to follow, including asthma, cystic fibrosis, and primary ciliary. The company was founded by John Fahy, and the CEO is Jim Shaffer. | Director/Board Member | - |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Director/Board Member | - |
Former positions of Thomas Mathers
Companies | Position | End |
---|---|---|
COLUCID PHARMACEUTICALS INC | Chief Executive Officer | 2017-06-30 |
CureFAktor Pharmaceuticals LLC | Director/Board Member | 2014-11-30 |
░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Thomas Mathers
US Military Academy | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
PFIZER, INC. | Health Technology |
Private companies | 16 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Cary Street Partners LLC
Cary Street Partners LLC Investment ManagersFinance Cary Street Partners LLC provides wealth management and investment banking services. It offers research & portfolio advisory, financial planning, insurance & estate planning and investment banking services. The company was founded by Mark M. Gambill and Thomas H. Tullidge Jr. in 2002 and is headquartered in Richmond, VA. | Finance |
CoLucid Pharmaceuticals, Inc.
CoLucid Pharmaceuticals, Inc. BiotechnologyHealth Technology CoLucid Pharmaceuticals, Inc. engaged in the development of therapeutics for neurological disorders. Its products included Lasmiditan, a neurally acting anti-migraine agent that is designed to delivered efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. The company was founded by James F. White and Arthur M. Pappas in 2005 and was headquartered in Cambridge, MA. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Snowden Pencer, Inc.
Snowden Pencer, Inc. Medical SpecialtiesHealth Technology Snowden Pencer, Inc. is a company that manufactures medical supplies. The company is based in Tucker, GA. Snowden Pencer was acquired by Cardinal Health, Inc. on March 05, 2004. | Health Technology |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Finance |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Health Technology |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Health Technology |
The United States Army (District of Columbia) | Government |
Cell Based Delivery, Inc. | |
Déclion Pharmaceuticals, Inc. | |
CureFAktor Pharmaceuticals LLC | |
Allievex Corp.
Allievex Corp. Pharmaceuticals: OtherHealth Technology Allievex Corp. operates as a biotechnology company. It develops therapies for the treatment of rare pediatric neurodegenerative diseases. The company was founded by Thomas P. Mathers and Eric H. Zanelli and is headquartered in Marblehead, MA. | Health Technology |
Lifesci Acquisition II Corp.
Lifesci Acquisition II Corp. Financial ConglomeratesFinance LifeSci Acquisition II Corp. operates as a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses for its initial business. The company was founded on December 18, 2019 and is headquartered in New York, NY. | Finance |
AM Pappas Life Science Ventures V | |
Aer Therapeutics, Inc.
Aer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aer Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Raleigh, NC. The company's mission is to advance the treatment paradigm for mucus mediated lung diseases. The company is dedicated to delivering a therapeutic solution to patients suffering from muco-obstructive lung diseases, with their initial focus being on chronic obstructive pulmonary disease (COPD) and other muco-obstructive lung diseases to follow, including asthma, cystic fibrosis, and primary ciliary. The company was founded by John Fahy, and the CEO is Jim Shaffer. | Health Technology |
- Stock Market
- Insiders
- Thomas Mathers